Chronic Myeloid Leukemia Clinical Trials

15 studies are recruiting for chronic myeloid leukemia in the United States right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

By city

Studies now recruiting

1. Phase II Study Assessing the Efficacy and Toxicity of Olverembatinib Monotherapy in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase

   To learn if olverembatinib can help to control newly diagnosed CML in the chronic phase.

   Stage

   Phase 2

   Ages

   18 and older

   Site

   MD Anderson Cancer Center, Houston, Texas

   Run by

   M.D. Anderson Cancer Center

   See if you can join NCT06817720 on ClinicalTrials.gov

2. Study of Olverembatinib (HQP1351) in Patients With CML-CP

   Study comparing efficacy and safety of olverembatinib (investigational arm) vs. bosutinib (control arm) in patients with CML-CP (Part A). Study will also evaluate efficacy and safety of olverembatinib (single-arm) in CML-CP patients with T315I mutation (Part B). Patients who meet ELN 2025 failure c…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Ascentage Investigative Site #1044, Birmingham, Alabama

   Locations

   163 in total

   Run by

   Ascentage Pharma Group Inc.

   See if you can join NCT06423911 on ClinicalTrials.gov

3. Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

   This study collects blood and tissue samples from patients with cancer and without cancer to evaluate tests for early cancer detection. Collecting and storing samples of blood and tissue from patients with and without cancer to study in the laboratory may help researchers develop tests for the earl…

   Stage

   Not phased

   Ages

   40 to 75

   Site

   Anchorage Associates in Radiation Medicine, Anchorage, Alaska

   Locations

   745 in total

   Run by

   Alliance for Clinical Trials in Oncology

   See if you can join NCT05334069 on ClinicalTrials.gov

4. Phase II Study Assessing the Safety and Efficacy of Dasatinib in Combination With Ropeginterferon in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase

   The goal of this clinical research study is to find out if treatment with a combination of dasatinib plus ropeginterferon can help to control CML-CP. The safety of this combination will also be studied.

   Stage

   Phase 2

   Ages

   18 and older

   Site

   The University of Texas M. D. Anderson Cancer Center, Houston, Texas

   Run by

   M.D. Anderson Cancer Center

   See if you can join NCT07269470 on ClinicalTrials.gov

5. Phase II Study Assessing Efficacy and Safety of Asciminib in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase.

   To learn if asciminib can help to control CML. The safety and effects of this drug will also be studied.

   Stage

   Phase 2

   Ages

   18 and older

   Site

   MD Anderson Cancer Center, Houston, Texas

   Run by

   M.D. Anderson Cancer Center

   See if you can join NCT06236724 on ClinicalTrials.gov

6. Alpha/Beta T Cell and CD19+ B Cell Depletion in Allogeneic Stem Cell Transplantation in Patients With Malignant Diseases

   This study will assess the safety, efficacy, and feasibility of ⍺/β CD3+ T-cell and CD19+ B-cell depletion in allogeneic stem cell transplantation in patients with acute lymphocytic leukemia (ALL), acute myeloid leukemia (AML), juvenile myelomonocytic leukemia (JMML), high risk myelodysplastic synd…

   Stage

   Phase 2

   Ages

   0 to 39

   Site

   University of Florida, Gainesville, Florida

   Run by

   University of Florida

   See if you can join NCT05800210 on ClinicalTrials.gov

7. HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant

   This phase I trial studies the side effects and best dose of CD4+ and CD8+ HA-1 T cell receptor (TCR) (HA-1 T TCR) T cells in treating patients with acute leukemia that persists, has come back (recurrent) or does not respond to treatment (refractory) following donor stem cell transplant. T cell rec…

   Stage

   Phase 1

   Ages

   Up to 80

   Site

   Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington

   Run by

   Fred Hutchinson Cancer Center

   See if you can join NCT03326921 on ClinicalTrials.gov

8. A Phase 1a/1b Study of ELVN-001 for the Treatment Chronic Myeloid Leukemia

   The purpose of this study is to evaluate the safety, tolerability and determine the recommended dose for further clinical evaluation of ELVN-001 in patients with chronic myeloid leukemia with and without T315I mutations in patients who are relapsed, refractory or intolerant to TKIs.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Memorial Sloan Kettering Cancer Center, New York, New York

   Locations

   45 in total

   Run by

   Enliven Therapeutics

   See if you can join NCT05304377 on ClinicalTrials.gov

9. Expanded/Activated Gamma Delta T-cell Infusion Following Hematopoietic Stem Cell Transplantation and Post-transplant Cyclophosphamide

   Gamma delta T-cells are part of the innate immune system with the ability to recognize malignant cells and kill them. This study uses gamma delta T-cells to maximize the anti-tumor response and minimize graft versus host disease (GVHD) in leukemic and myelodysplastic patients who have had a partial…

   Stage

   Phase 1

   Ages

   18 to 65

   Site

   University of Kansas Cancer Center, Westwood, Kansas

   Locations

   2 in total

   Run by

   University of Kansas Medical Center

   See if you can join NCT03533816 on ClinicalTrials.gov

10. A Study of CBX-250 in Participants With Relapsed or Refractory Myeloid Leukemias

    Study CBX-250-001 is a Phase 1, open-label, dose-escalation study of CBX-250 in participants with relapsed/refractory AML, HR-MDS, CMML, and CML. Participants aged ≥ 12 years are planned to be enrolled. CBX-250 will initially be investigated on a fixed step-up dosing schedule. CBX-250 will be admin…

    Stage

    Phase 1

    Ages

    12 and older

    Site

    City of Hope, Duarte, California

    Locations

    11 in total

    Run by

    Crossbow Therapeutics, Inc.

    See if you can join NCT06994676 on ClinicalTrials.gov

11. Impact of Personality on Adherence to Tyrosine Kinase Inhibitor Therapy in Pts w/Chronic Myeloid Leukemia

    This is an observational pilot study to examine the association between a patient's personality and adherence to tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia.

    Stage

    Not phased

    Ages

    18 and older

    Site

    Chao Family Comprehensive Cancer Center University of California, Irvine, Orange, California

    Run by

    University of California, Irvine

    See if you can join NCT06229860 on ClinicalTrials.gov

12. A Phase 1/2 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of TERN-701 in Participants With Chronic Myeloid Leukemia (CARDINAL)

    The goal of the study is to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy of TERN-701, a highly selective allosteric inhibitor of BCR-ABL1, in participants with previously treated chronic phase - chronic myeloid leukemia (CP-CML). The study has two parts: Part 1…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    University of Alabama Medicine (UAB Medicine), Birmingham, Alabama

    Locations

    54 in total

    Run by

    Terns, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

    See if you can join NCT06163430 on ClinicalTrials.gov

13. Selumetinib and Azacitidine in High Risk Chronic Blood Cancers

    This is a phase I, open-label, dose-escalation study to determine the MTD of selumetinib when combined with the standard dose of azacitidine. Treatment will begin within 28 days of screening procedures. Treatment will continue indefinitely, provided that the patient continues to derive benefit. A p…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    The University of Chicago, Chicago, Illinois

    Run by

    University of Chicago

    See if you can join NCT03326310 on ClinicalTrials.gov

14. Study of HQP1351 in Subjects With Refractory CML and Ph+ ALL

    A multi-center, open-label, randomized, phase Ib study to evaluate the pharmacokinetics (PK) of HQP1351 and to determine the recommended phase 2 dose (RP2D) of HQP1351 in subjects with CML chronic phase (CP), accelerated phase (AP), or blast phase (BP) or with Ph+ ALL, who have experienced resistan…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    University of Alabama at Birmingham, Birmingham, Alabama

    Locations

    9 in total

    Run by

    Ascentage Pharma Group Inc.

    See if you can join NCT04260022 on ClinicalTrials.gov

15. Darzalex Faspro (Daratumumab and Hyaluronidase-fihj) Before Standard Desensitization and Allogeneic Peripheral Blood Stem Cell Transplantation in Adult Patients at High-risk for Primary Graft Failure Secondary to Donor Specific Antibodies

    This research is being done to investigate the safety and effectiveness of Darzalex Faspro (daratumumab and hyaluronidase-fihj) (a monoclonal antibody that targets plasma cells that make antibodies) and whether it can lower donor specific antibodies (DSA) levels to low enough levels to permit patie…

    Stage

    EARLY_Phase 1

    Ages

    18 and older

    Site

    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland

    Run by

    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

    See if you can join NCT06398457 on ClinicalTrials.gov